

Faculty

Chairs:

Dr Lars Borris

Aarhus University Hospital
Aarhus, Denmark

Dr Patrick Mouret

Orthopädische Klinik, Städtische Klinik
Frankfurt, Germany

Speakers:

Dr Patrick Mouret

Orthopädische Klinik, Städtische Klinik
Frankfurt, Germany

Dr Camilla Ryge

Hørsholm Hospital
Hørsholm, Denmark

Dr Alexander Kidd

South West London Elective Orthopaedic Centre
London, UK

Dr Näder Helmy

Klinik für Orthopädie und Traumatologie
Solothurn, Switzerland

Rivaroxaban...Oral, Once Daily, in Orthopaedic Practice... Experience that Counts

Chaired by Lars Borris and Patrick Mouret


Thursday 2 June 2011, 12:30–14:00

Neptune 2, Exhibition Area, Bella Center, Copenhagen, Denmark

A Satellite Symposium sponsored by Bayer HealthCare Pharmaceuticals
at the 12th Congress of the European Federation of National Associations of Orthopaedics and Traumatology
Copenhagen, Denmark
1–4 June 2011

Sponsored by Bayer HealthCare Pharmaceuticals

The marketing authorization for rivaroxaban may vary from country to country. In Denmark, rivaroxaban is approved for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.



Chairmen's Welcome

Dear Colleagues,

We are delighted to host this Satellite Symposium at the 12th Congress of the European Federation of National Associations of Orthopaedics and Traumatology held this year in Copenhagen. We invite you to attend presentations that will focus on the experience gained with the oral, once daily, direct Factor Xa inhibitor rivaroxaban to date with a focus on practical real-life aspects.


Dr Patrick Mouret will open the Symposium with an overview of advances in anticoagulation for thromboprophylaxis, highlighting that new oral anticoagulants have become an integral part in the post-operative period by providing a continuum of care for inpatient and outpatient thromboprophylaxis. Dr Camilla Ryge will then discuss data from the RECORD programme that compared rivaroxaban with enoxaparin in more than 12,500 patients and will highlight the similarities and differences between patients who participated in rivaroxaban clinical trials versus those treated in real-life clinical practice, with a focus on the practical considerations. Next, Dr Alexander Kidd will provide insight into the new ESA anaesthesia guidelines, in terms of the use of new oral anticoagulants, and will present a case study relating to the use of rivaroxaban and anaesthesia. Following this, Dr Ryge and Dr Kidd will participate in an exciting case discussion about the practical considerations arising from the use of rivaroxaban from the perspectives of a surgeon and an anaesthetist. In the concluding presentation, Dr Näder Helmy will consider the practical implications of VTE prophylaxis following total hip/knee arthroplasty, focusing on post-surgical safety outcomes and experience gained since the introduction of rivaroxaban.

We hope that you will be able to join us for what promises to be a highly interesting, practical and interactive programme.

Kind regards,



Lars Borris



Patrick Mouret

Rivaroxaban...Oral, Once Daily, in Orthopaedic Practice...Experience that Counts

Chaired by Lars Borris and Patrick Mouret

Thursday 2 June 2011, 12:30–14:00

Neptune 2, Exhibition Area, Bella Center, Copenhagen, Denmark

A Satellite Symposium sponsored by Bayer HealthCare Pharmaceuticals at the EFORT Annual Congress 2011, 1–4 June 2011

12:30	Welcome and introduction Lars Borris, Denmark
12:35	New ways of thinking in orthopaedic anticoagulation Patrick Mouret, Germany
12:45	From clinical data to extensive real-life experience Camilla Ryge, Denmark
13:00	How will new anaesthesia guidelines affect clinical practice? Alexander Kidd, United Kingdom
13:15	Case discussion – the perspectives of a surgeon and an anaesthetist Camilla Ryge, Denmark Alexander Kidd, United Kingdom
13:30	Practical implications of oral thromboprophylaxis in daily practice Näder Helmy, Switzerland
13:45	Summary Patrick Mouret, Germany

